Edition:
United States

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

19.10USD
4:00pm EDT
Change (% chg)

$-0.45 (-2.30%)
Prev Close
$19.55
Open
$19.70
Day's High
$19.70
Day's Low
$18.60
Volume
119,896
Avg. Vol
47,909
52-wk High
$20.05
52-wk Low
$11.30

OTIC.OQ

Chart for OTIC.OQ

About

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $591.52
Shares Outstanding(Mil.): 30.26
Dividend: --
Yield (%): --

Financials

  OTIC.OQ Industry Sector
P/E (TTM): -- 212.70 15.75
EPS (TTM): -3.67 -- --
ROI: -50.85 -8.82 -8.37
ROE: -51.04 -10.46 -7.95

BRIEF-FDA accepts Otonomy's expanded label application for Otiprio

* Otonomy announces FDA acceptance of Otiprio supplemental new drug application filing for acute otitis externa

Jul 18 2017

BRIEF-Otonomy announces successful end-of-phase 2 review by FDA for Otiprio

* Otonomy announces successful end-of-Phase 2 review by FDA for Otiprio® in acute otitis media with tympanostomy tubes

Jun 22 2017

BRIEF-Otonomy Inc reports Q1 loss per share $0.89

* Otonomy reports first quarter 2017 financial results and provides corporate update

May 04 2017

Two-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies

Doctors have struggled for years to deliver medication effectively to the inner ear, but two companies are vying to be first to introduce new treatments which, if successful, could together chalk up some $800 million in peak sales.

Apr 20 2017

Two-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies

April 20 Doctors have struggled for years to deliver medication effectively to the inner ear, but two companies are vying to be first to introduce new treatments which, if successful, could together chalk up some $800 million in peak sales.

Apr 20 2017

BRIEF-Otonomy loss per share $0.88

* Otonomy reports fourth quarter and full year 2016 financial results and provides corporate update

Mar 02 2017

BRIEF-Otonomy qtrly loss per share $0.88

* Says topline data for oto-104 phase 3 trials expected in 2H2017

Mar 02 2017

Earnings vs. Estimates